New thesis examines long-term effects of MS treatment on the immune system

Long-term treatment with therapies that target B cells can affect antibody levels and, in some patients, increase susceptibility to infections. In her doctoral thesis, “In the wake of B-cell depletion – Immunoglobulin change and neutropenia in multiple sclerosis”, Susanna Hallberg examines how these effects can be identified and monitored in people with multiple sclerosis (MS).
Anti-CD20 therapies, such as rituximab, target B cells, a type of white blood cell involved both in the immune system and in the disease process in MS. The therapies suppress inflammatory disease activity, but prolonged treatment can also affect other parts of the immune system.
Susanna Hallberg’s thesis focuses particularly on changes in immunoglobulins, or antibodies, as well as infections and late-onset neutropenia, a condition in which levels of neutrophils, another type of white blood cell, fall unexpectedly.

“My thesis explores the long-term effects of anti-CD20 therapies on the immune system and infection risk in people with MS. By using data from national health registers and medical records, we can study uncommon side effects that may not become apparent in clinical trials,” says Susanna Hallberg, doctoral student at the Department of Clinical Sciences, Danderyd Hospital.
Antibody levels declined over time
The studies showed that antibody levels gradually decreased during long-term treatment with rituximab. Nearly one in ten patients developed low immunoglobulin levels. Age and previous MS treatments influenced these changes, while a faster decline in antibody levels was linked to slower recovery of B cells after treatment.
The thesis also examined treatment before pregnancy. Women who already had low immunoglobulin levels before conception could have an increased risk of low levels and infections during and after pregnancy following anti-CD20 treatment.
Monitoring may support safer treatment
Another part of the thesis examined late-onset neutropenia. The condition was more common among people with MS than previously recognised. Most cases were mild, but some patients developed severe infections requiring hospital care. All infections resolved, and restarting rituximab was safe for most patients in the study.
“Monitoring immunoglobulin levels, neutrophil counts and B-cell recovery may help identify patients who have an increased risk of infections. This could support more individualised treatment while maintaining its effectiveness,” says Susanna Hallberg.
Susanna Hallberg plans to return to clinical work at the MS clinic at the Academic Specialist Centre in Stockholm.
“Working closely with patients and colleagues is important and provides insight into the impact of chronic illnesses and treatments. These experiences often generate the most important research questions, and I hope to continue combining clinical work with research, teaching, and healthcare improvement”, says Susanna Hallberg.
The thesis work was supervised by Anders Svenningsson, professor at the same department, and Katarina Fink, assistant professor at the Department of Clinical Neuroscience. The public defence will take place on 27 November 2026, in Aulan at Danderyd Hospital.